Document:

WARRANT TO PURCHASE COMMON STOCK

                              (CONVERSION WARRANTS)

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT FOR DISTRIBUTION, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED NEITHER THE WARRANT NOR THE SHARES MAY BE SOLD, PLEDGED, OR
OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT
OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE
COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. THIS WARRANT
MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION
PRECEDENT TO THE SALE, PLEDGE OR OTHER TRANSFER OF ANY INTEREST IN THIS WARRANT
OR THE SHARES ISSUABLE HEREUNDER.

Issuer:  DNAPrint Genomics, Inc.
Class of Stock: Common Stock
Issue Date: November ___, 2003
Expiration Date: November ___, 2006

      THIS WARRANT TO PURCHASE COMMON STOCK is being issued pursuant to that
certain Securities Purchase Agreement dated as of the date hereof (the "Purchase
Agreement") between DNAPrint Genomics, Inc., a Utah corporation (the "Company")
and La Jolla Cove Investors, Inc. ("Holder").

            1.1 Warrants. The Company hereby grants to Holder the right to
purchase that number of shares of the Company's Common Stock (the "Shares" or
"Warrant Shares") equal to fifteen (15) times the number of shares of Common
Stock issued to Holder from time to time pursuant to the conversion of the
Debenture (as such term is defined in the Purchase Agreement). For avoidance of
doubt, this Warrant must be exercised concurrently with to the issuance of a
Conversion Notice under the Debenture. The date that the Holder issues a
Conversion Notice under the Debenture is hereafter referred to as the
"Conversion Date." Defined terms not defined herein shall have the meanings
ascribed to them in the Debenture or the Purchase Agreement. Holder agrees that,
beginning in the first full calendar month after the Registration Statement is
declared effective,

Holder will exercise at least 5% of the Warrants per calendar month, in
conjunction with issuance of Conversion Notices under the Debentue, provided
that the Common Shares are available, registered and freely tradable. In the
event Holder breaches this provision, Holder shall not be entitled to collect
interest on the Debenture for that month. In the event the Holder breaches this
provision more than once in any twelve month period, at the option of the
Company, this Agreement, the Registration Rights Agreement and the Securities
Purchase Agreement shall terminate.

This Warrant shall expire and Holder shall no longer be able to purchase the
Warrant Shares on November ___, 2006.

                                       1
--------------                                                    --------------
Initials                                                                Initials
<PAGE>

                                   ARTICLE 2
                                    EXERCISE

            2.1 Method of Exercise. Holder may exercise this Warrant by
delivering a duly executed Warrant Notice of Exercise in substantially the form
attached as Appendix 1 to the principal office of the Company, along with a
check payable to the Company for the aggregate Exercise Price for the Shares
being purchased.

            2.2 Delivery of Certificate and New Warrant. As promptly as
practicable after the receipt of the Warrant Notice of Exercise, but in any
event not more than three (3) Business Days after the Company's receipt of the
Warrant Notice of Exercise, the Company shall issue the Shares and cause to be
mailed for delivery by overnight courier, or if a Registration Statement
covering the Shares has been declared effective by the SEC cause to be
electronically transferred, to Holder a certificate representing the Shares
acquired and, if this Warrant has not been fully exercised and has not expired,
a new Warrant substantially in the form of this Warrant representing the right
to acquire the portion of the Shares not so acquired.

            2.3 Replacement of Warrants. On receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of loss, theft or destruction, on delivery of an
indemnity agreement reasonably satisfactory in form and amount to the Company
or, in the case of mutilation, or surrender and cancellation of this Warrant,
the Company at its expense shall execute and deliver, in lieu of this Warrant, a
new warrant of like tenor.

            2.4 Exercise Price. The Exercise Price of this Warrant shall be
equal to the Conversion Price under the Debenture as of the date of Exercise.

                                   ARTICLE 3
                            ADJUSTMENT TO THE SHARES

      The number of Shares purchasable upon the exercise of this Warrant and the
Exercise Price shall be subject to adjustment form time to time upon the
occurrence of certain events, as follows:

            3.1 Reclassification. In case of any reclassification or change of
outstanding securities of the class issuable upon exercise of this Warrant then,
and in any such case, the Holder, upon the exercise hereof at any time after the
consummation of such reclassification or change, shall be entitled to receive in
lieu of each Share theretofore issuable upon exercise of this Warrant, the kind
and amount of shares of stock, other securities, money and/or property received
upon such reclassification or change by a holder of one Share. The provisions of
this Section 2.1 shall similarly apply to successive reclassifications or
changes.

            3.2 Subdivision or Combination of Shares. If the Company at any time
while this Warrant remains outstanding and unexpired shall subdivide or combine
its Shares, the Exercise Price shall be proportionately decreased in the case of
a subdivision or increased in the case of a combination.

                                       2
--------------                                                    --------------
Initials                                                                Initials
<PAGE>

            3.3 Stock Dividends. If the Company, at any time while this Warrant
is outstanding shall pay a dividend with respect to its Shares payable in
Shares, or make any other distribution of Shares with respect to Shares (except
any distribution specifically provided for in Section 2.1 and Section 2.2
above), then the Exercise Price shall be adjusted, effective from and after the
date of determination of shareholders entitled to received such dividend or
distribution, to that price determined by multiplying the Exercise Price in
effect immediately prior to such date of determination by a fraction, (a) the
numerator of which shall be the total number of Shares outstanding immediately
prior to such dividend or distribution, and (b) the denominator of which shall
be the total number of Shares outstanding immediately after such dividend or
distribution.

            3.4 Non-Cash Dividends. If the Company at any time while this
Warrant is outstanding shall pay a dividend with respect to Shares payable in
securities other than Shares or other non-cash property, or make any other
distribution of such securities or property with respect to Shares (except any
distribution specifically provided for in Section 2.1 and Section 2.2 above),
then this Warrant shall represent the right to acquire upon exercise of this
Warrant such securities or property which a holder of Shares would have been
entitled to receive upon such dividend or distribution, without the payment by
the Holder of any additional consideration for such securities or property.

            3.5 Effect of Reorganization and Asset Sales. If any (i)
reorganization or reclassification of the Common Stock (ii) consolidation or
merger of the Company with or into another corporation, or (iii) sale or all or
substantially all of the Company's operating assets to another corporation
followed by a liquidation of the Company ( (any such transaction shall be
referred to herein as an "Event"), is effected in such a way that holders of
common Stock are entitled to receive securities and/or assets as a result of
their Common Stock ownership, the Holder, upon exercise of this Warrant, shall
be entitled to receive such shares of stock securities or assets which the
Holder would have received had it fully exercised this Warrant on or prior the
record date for such Event. The Company shall not merge into or consolidate with
another corporation or sell all of its assets to another corporation for a
consideration consisting primarily of securities of such corporation, unless the
successor or acquiring corporation, as the case may be, shall expressly assume
the due and punctual observance and performance of each and every covenant and
condition of this Warrant to be performed or observed by the Company and all of
the obligations and liabilities hereunder, subject to such modification as shall
be necessary to provide for adjustments which shall be as nearly equivalent as
practicable to the adjustments provided for in this Section 2. The foregoing
provisions shall similarly apply to successive mergers, consolidations or sales
of assets.

            3.6 Adjustment of Number of Shares. Upon each adjustment in the
Exercise Price, the number of Shares shall be adjusted, to the nearest whole
share, to the product obtained by multiplying the number of Shares, purchasable
immediately prior to such adjustment by a fraction, the numerator of which is
the Exercise Price prior to such adjustment and the denominator of which shall
be the Exercise Price immediately thereafter.

            3.7 No Impairment. The Company shall not, by amendment of its
articles of incorporation or through a reorganization, transfer of assets,
consolidation, merger, dissolution, issue, or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or

                                       3
--------------                                                    --------------
Initials                                                                Initials
<PAGE>

performance of any of the terms to be observed or performed under this Warrant
by the Company, but shall at all times in good faith assist in carrying out all
of the provisions of this Warrant and in taking all such action as may be
reasonably necessary or appropriate to protect Holder's rights hereunder against
impairment. If the Company takes any action affecting its Common Stock other
than as described above that adversely affects Holder's rights under this
Warrant, the Exercise Price shall be adjusted downward and the number of Shares
issuable upon exercise of this Warrant shall be adjusted upward in such a manner
that the aggregate Exercise Price of this Warrant is unchanged.

            3.8 Fractional Shares. No fractional Shares shall be issuable upon
the exercise of this Warrant, and the number of Shares to be issued shall be
rounded down to the nearest whole Share.

            3.9 Certificate as to Adjustments. Upon any adjustment of the
Exercise Price, the Company, at its expense, shall compute such adjustment and
furnish Holder with a certificate of its Chief Financial Officer setting forth
such adjustment and the facts upon which such adjustment is based. The Company
shall, upon written request, furnish Holder a certificate setting forth the
Exercise Price in effect upon the date thereof and the series of adjustments
leading to such Exercise Price.

            3.10 No Rights of Shareholders. This Warrant does not entitle Holder
to any voting rights or any other rights as a shareholder of the Company prior
to the exercise of Holder's right to purchase Shares as provided herein.

                                   ARTICLE 4
                  REPRESENTATIONS AND COVENANTS OF THE COMPANY

            4.1 Representations and Warranties. The Company hereby represents
and warrants to Holder that all Shares which may be issued upon the exercise of
the purchase right represented by this Warrant, shall, upon issuance, be duly
authorized, validly issued, fully paid and nonasessable, and free of any liens
and encumbrances.

            4.2 Notice of Certain Events. If the company proposes at any time
(a) to declare any dividend or distribution upon its Common Stock, whether in
cash, property, stock, or other securities and whether or not a regular cash
dividend; (b) to offer for subscription pro rata to the holders of any class or
series of its stock any additional shares of stock of any class or series or
other rights; (c) to effect any reclassification or recapitalization of Common
Stock; (d) to merge or consolidate with or into any other corporation, or sell,
lease, license, or convey all or substantially all of its assets, or to
liquidate, dissolve or wind up; or (e) offer holders of registration rights the
opportunity to participate in an underwritten public offering of the Company's
securities for cash, then, in connection with each such event, the Company shall
give Holder (1) at least 20 days prior written notice of the date on which a
record will be taken for such dividend, distribution, or subscription rights
(and specifying the date on which the holders of Common Stock will be entitled
thereto) or for determining rights to vote, if any, in respect of the matters
referred to in (c) and (d) above; (2) in the case of the matters referred to in
(c) and (d) above at least 20 days prior written notice of the date when the
same will take place (and specifying the date on which the holders of Common
Stock will be entitled to exchange their

                                       4
--------------                                                    --------------
Initials                                                                Initials
<PAGE>

Common Stock for securities or other property deliverable upon the occurrence of
such event); and (3) in the case of the matter referred to in (e) above, the
same notice as is given to the holders of such registration rights.

            4.3 Information Rights. So long as Holder holds this Warrant and/or
any of the Shares, the company shall deliver to Holder (a) promptly after
mailing, copies of all notices or other written communications to the
shareholders of the Company, (b) within ninety (90) days of their availability,
the annual audited financial statements of the Company certified by independent
public accountants of recognized standing, and (c) within forty-five (45) days
after the end of each fiscal quarter or each fiscal year, the Company's
quarterly, unaudited financial statements.

            4.4 Reservation of Warrant Shares. The Company has reserved and will
keep available, out of the authorized and unissued shares of Common Stock, the
full number of shares sufficient to provide for the exercise of the rights of
purchase represented by this Warrant.

            4.5 Registration Rights. If Holder exercises this Warrant and
purchases some or all of the Shares, Holder shall have the Registration Rights
set forth in that certain Registration Rights Agreement executed concurrently
therewith.

                                   ARTICLE 5
                   REPRESENTATIONS AND COVENANTS OF THE HOLDER

            5.1 Private Issue. Holder understands (i) that the Shares issuable
upon exercise of Holder's rights contained in the Warrant are not registered
under the Act or qualified under applicable state securities laws on the ground
that the issuance contemplated by the Warrant will be exempt from the
registration and qualifications requirements thereof, and (ii) that the
Company's reliance on such exemption is predicated on Holder's representations
set forth in this Article 4.

            5.2 Financial Risk. Holder has such knowledge and experience in
financial and business matters as to be capable of evaluating the merits and
risks of its investment and has the ability to bear the economic risks of its
investment.

            5.3 Risk of No Registration. Holder understands that if the Company
does not register with the Securities and Exchange Commission pursuant to
Section 12 of the Act, or file reports pursuant to Section 15(d), of the
Securities Exchange Act of 1934 (the "1934 Act"), or if a registration statement
covering the securities under the Act is not in effect when it desires to sell
(i) the right to purchase Shares pursuant to the Warrant, or (ii) the Shares
issuable upon exercise of the right to purchase, it may be required to hold such
securities for an indefinite period.

            5.4 Accredited Investor. Holder is an "accredited investor," as such
term is defined in Regulation D promulgated pursuant to the Act.

                                       5
--------------                                                    --------------
Initials                                                                Initials
<PAGE>

                                    ARTICLE 6
                                  MISCELLANEOUS

            6.1 Term. This Warrant is exercisable, in whole or in part, at any
time and from time to time on or after the Conversion Date and on or before the
Expiration Date set forth above.

            6.2 Compliance with Securities Laws on Transfer. This Warrant may
not be transferred or assigned in whole or in part without compliance with
applicable federal and state securities laws by the transferor and the
transferee (including, without limitation, the delivery of investment
representation letters and legal opinions reasonably satisfactory to the
Company, as reasonably requested by the Company). The Company shall not require
Holder to provide an opinion of counsel if the transfer is to an affiliate of
Holder.

            6.3 Transfer Procedure. Holder shall have the right without the
consent of the Company to transfer or assign in whole or in part this Warrant
and the Shares issuable upon exercise of this Warrant. Holder agrees that unless
there is in effect a registration statement under the Act covering the proposed
transfer of all or part of this Warrant, prior to any such proposed transfer the
Holder shall give written notice thereof to the Company (a "Transfer Notice").
Each Transfer Notice shall describe the manner and circumstances of the proposed
transfer in reasonable detail and, if the company so requests, shall be
accompanied by an opinion of legal counsel, in a form reasonably satisfactory to
the Company, to the effect that the proposed transfer may be effected without
registration under the Act; provided that the Company will not require opinions
of counsel for transactions involving transfers to affiliates or pursuant to
Rule 144 promulgated by the Securities and Exchange Commission under the act,
except in unusual circumstances.

            6.4 Notices, etc. All notices and other communications required or
permitted hereunder shall be in writing and shall be delivered personally, or
sent by telecopier machine or by a nationally recognized overnight courier
service, and shall be deemed given when so delivered personally, or by
telecopier machine or overnight courier service as follows:

            if to the Company, to:

            DNAPrint Genomics, Inc.
            900 Cocoanut Ave.
            Sarasota, Florida 34236
            Telephone: 941-366-3400
            Facsimile: 941-952-9770

            if to the Holder, to:

            La Jolla Cove Investors, Inc.
            7817 Herschel Avenue, Suite 200
            La Jolla, CA 92037
            Telephone: 858-551-8789
            Facsimile: 858-551-8779

                                       6
--------------                                                    --------------
Initials                                                                Initials
<PAGE>

or at such other address as the Company shall have furnished to the Holder. Each
such notice or other communication shall for all purposes of this agreement be
treated as effective or having been given when delivered if delivered
personally, or, if sent by mail, at the earlier of its receipt or five days
after the same has been deposited in a regularly maintained receptacle for the
deposit of the United States mail, addressed and mailed as aforesaid.

      6.5 Counterparts. This agreement may be executed in any number of
counterparts, each of which shall be enforceable against the parties actually
executing such counterparts, and all of which together shall constitute one
instrument. Facsimile execution shall be deemed originals.

      6.6 Waiver. This Warrant and any term hereof may be changed, waived,
discharged or terminated only by an instrument in writing signed by the party
against which enforcement of such change, waiver, discharge or termination is
sought.

      6.7 Attorneys Fees. In the event of any dispute between the parties
concerning the terms and provisions of this Warrant, the party prevailing in
such dispute shall be entitled to collect from the other party all costs
incurred in such dispute, including reasonable attorneys fees.

      6.8 Governing Law; Jurisdiction. This Warrant shall be governed by and
construed in accordance with the laws of the State of California, without giving
effect to its principles regarding conflicts of law. Each of the parties hereto
consents to the jurisdiction of the federal courts whose districts encompass any
part of the City of San Diego or the state courts of the State of California
sitting in the City of San Diego in connection with any dispute arising under
this Warrant and hereby waives, to the maximum extent permitted by law, any
objection including any objection based on forum non conveniens, to the bringing
of any such proceeding in such jurisdictions.

      IN WITNESS WHEREOF, the parties hereto have duly caused this Warrant to
Purchase Common Stock to be executed and delivered on the date first above
written.

DNAPrint Genomics, Inc.                 La Jolla Cove Investors, Inc.

By:________________________________     By:_____________________________________

Title:_____________________________     Title:__________________________________

                                       7
--------------                                                    --------------
Initials                                                                Initials
<PAGE>

                                   APPENDIX 1

                           WARRANT NOTICE OF EXERCISE

      1. The undersigned hereby elects to purchase _____ shares of the Common
Stock of DNAPrint Genomics, Inc. pursuant to the terms of the Warrant to
Purchase Common Stock issued by DNAPrint Genomics, Inc. on November ___, 2003
and tenders herewith payment of the purchase price of such shares in full.

      2. Please issue a certificate or certificates representing said shares in
the name of the undersigned or in such other name as is specified below:

                                        ________________________________________

                                        ________________________________________

                                        ________________________________________
                                        (Name and Address)

      3. The undersigned makes the representations and covenants set forth in
Article 4 of the Warrant to Purchase Common Stock.

___________________________________
(Signature)

___________________________________
(Date)

                                       8
--------------                                                    --------------
Initials                                                                InitialsLA JOLLA COVE INVESTORS, INC.
                          1795 UNION STREET, 3rd FLOOR
                         SAN FRANCISCO, CALIFORNIA 94123
                            TELEPHONE: (415) 409-8703
                            FACSIMILE: (415) 409-8704
                            E-MAIL: LJCI@PACBELL.NET

LA JOLLA                      www.ljcinvestors.com                 SAN FRANCISCO
--------------------------------------------------------------------------------

                               November ___, 2003

Mr. _______________________________
DNAPrint Genomics, Inc.
900 Cocoanut Ave
Sarasota, FL 34236

              Re: Registration Statement Legal and Accounting Fees

Dear _____________________________:

This letter will set forth our agreement for the payment of the attorneys' and
accounting fees necessary for the filing of a registration statement by DNAPrint
Genomics, Inc. ("DNA") to cover, among other things, the shares of DNA common
stock necessary for the 8% Convertible Debenture and the warrants issued to La
Jolla Cove Investors, Inc. ("LJCI").

Under the Securities Purchase Agreement, LJCI is to advance $250,000 to DNA upon
closing. It is agreed that LJCI will retain $50,000 of the initial advance for
the payment of legal and accounting fees for the filing of the Registration
Statement for the Conversion Shares and the Warrant Shares. The $50,000 will be
paid to the attorneys and accountants once the Registration Statement has been
declared effective. At LJCI's sole discretion, all or any part of the $50,000
may be paid to the attorneys and accountants prior to the Registration Statement
being declared effective.

DNA agrees that it is responsible for the payment of legal and accounting fees,
if any, over and above the $50,000 covered herein.

If this letter correctly reflects our agreement regarding the payment of DNA's
attorneys' and accounting fees for the preparation and filing of the
Registration Statement, please acknowledge your agreement by signing below.

Sincerely,

Travis W. Huff
Portfolio Manager

DNAPrint Genomics, Inc.

By:________________________________

Title:_____________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}]]